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Weekly Paclitaxel and Carboplatin in Unresectable Stage III
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Charles Williams, MD,* Dung-Tsa Chen, PhD,§ Harvey Greenberg, MD,† Frank Walsh, MD,
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Introduction: The survival for patients with locally advanced,
unresectable non-small cell lung cancer receiving standard of care
concomitant chemoradiation remains disappointingly low. A reduc-
tion in both local and distant recurrence is needed to improve
patients’ outcome. Performing molecular studies on serially col-
lected tumor specimens may result in a better selection of therapeu-
tic options.
Methods: We conducted a phase II single-institution trial of two
cycles of induction chemotherapy with gemcitabine and carboplatin
followed by high-dose conformal radiation concomitant with weekly
paclitaxel and carboplatin in 39 patients. The trial required a dedi-
cated tumor biopsy before treatment initiation. In addition, tumor
biopsies were requested, if safely feasible, before initiation of
chemoradiation and 2 months after completion all therapy.
Results: Induction chemotherapy was well tolerated, and 38 patients
proceeded with chemoradiation. The mean delivered radiation dose
was 70.2 Gy, 23 patients received the full dose of 74 Gy, and 19
patients completed all treatment on schedule without dose reduc-
tions or delays. Median overall and progression-free survivals were
22.7 and 14.3 months, respectively. A total of 82 procedures,
including 46 transthoracic core needle biopsies, were performed.
Thirteen patients had all three serial tumor biopsies. Three of these
procedures resulted in complications that required an intervention;
all for the treatment of a biopsy-induced pneumothorax.
Conclusions: We conclude that induction gemcitabine/carboplatin
followed by concurrent paclitaxel/carboplatin with conformal radi-
ation to 74 Gy is safe and tolerable with promising efficacy. We
demonstrated that dedicated and serial tumor collections are safe,
feasible, and acceptable for patients with non-small cell lung cancer.
Key Words: Non-small-cell lung cancer, Conformal radiation,
Gemcitabine, Carboplatin, Paclitaxel, ERCC1, RRM1.
(J Thorac Oncol. 2011;6: 553–558)
The achievement of long-term disease control throughreduction of local recurrence and metastatic spread re-
mains the key goal in the treatment of locally advanced,
inoperable non-small cell lung cancer (NSCLC), which ac-
counts for approximately 25% of cases (http://seer.cancer.
gov/data/).1 The addition of systemic therapy to radiotherapy
was a major step toward this goal, and it has become the
standard of care (http://www.nccn.org). Clinical research has
addressed the sequencing of both modalities, and concurrent
therapy is superior to a sequential approach.2–5 To further
improve outcomes, induction chemotherapy to reduce sys-
temic disease burden followed by concurrent therapy for
improved local control has been suggested as a promising
approach in a retrospective analysis.6 Unfortunately, a pro-
spective randomized phase III trial, designed to formally
address this question, was closed early due to poor accrual.
Nevertheless, results suggested an improvement in overall
survival (OS), although not statistically significant, for pa-
tients receiving induction chemotherapy followed by chemo-
radiation, as opposed to chemoradiation alone.6
The advent of modern radiotherapeutic techniques to
safely escalate radiation doses is one approach to reduce local
recurrence rates. An initial phase I/II trial conducted by
investigators at the University of North Carolina demon-
strated that it was safe to increase the radiation dose from 60
to 74 Gy, in conjunction with induction and concurrent
paclitaxel/carboplatin therapy.7–9
In this study, we report our result from a prospective
phase II trial of induction gemcitabine/carboplatin followed
by concurrent radiotherapy to 74 Gy with weekly paclitaxel/
carboplatin. The choice of agents and sequencing was based
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on available data at the time of trial design. Chemoradiation
followed by consolidation docetaxel was viewed by many as
the “gold standard” with a median OS of 26 months.10
Nevertheless, the administration of consolidation chemother-
apy was difficult (78% of patients started consolidation treat-
ment and 75% completed this treatment). Induction chemo-
therapy had been considered as a reasonable alternate
approach, with gemcitabine and platinum providing the long-
est median OS (18.3 months) compared with paclitaxel/
platinum or vinorelbine/platinum.11 In addition to reporting
safety, efficacy, and feasibility of this chosen regimen, we
also report our experience with dedicated serial tumor biop-
sies, which were required for molecular investigations before
treatment initiation and after induction therapy and 2 months
after completion of all therapy if feasible. The predictive
utilities of mRNA expression values for the genes ERCC1
and RRM1 have been previously reported.12
PATIENTS AND METHODS
Eligibility Criteria
The study was approved by the University of South
Florida’s Institutional Review Board (ClinicalTrials.gov no.
NCT00226590). Eligible patients had to have histologically
confirmed adenocarcinoma, squamous cell carcinoma, or
large cell carcinoma stage IIIA or “dry” IIIB according to
version 6 AJCC staging criteria. Histological confirmation of
N2 nodal involvement was required in patients with medias-
tinal lymph node enlargement of less than 2 cm on computed
tomography (CT) scans of the chest and upper abdomen or
suspicious on whole body [18F]-fluorodeoxyglucose positron
emission tomography (PET), and it was not mandatory for
patients with obvious nodal involvement (2.0 cm or greater).
CT with intravenous contrast, PET, magnetic resonance im-
aging or CT of the brain with intravenous contrast, Eastern
Cooperative Oncology Group performance status of 0 or 1,
and weight loss of 5% in the preceding 3 months were
required. No prior systemic chemotherapy or thoracic radio-
therapy was permitted. History of a prior or concomitant
malignancy in the past 5 years was an exclusion criterion,
except for surgically cured basal cell carcinoma of the skin or
carcinoma in situ of the cervix. Additionally, no concomitant
life threatening or uncontrolled serious medical illness such
as cardiac arrhythmia, end stage congestive heart failure, liver
disease with significant hepatic insufficiency, or organic brain
syndrome were permitted. Laboratory testing had to demon-
strate adequate marrow reserve, and hepatic and renal func-
tion. The informed consent document explained the therapeu-
tic interventions and the required tumor biopsies (see later).
Therapeutic Protocol
Induction chemotherapy consisted of two cycles of
gemcitabine (1000 mg/m2) on days 1 and 8 and carboplatin
(area under the curve, 5) on day 1 given at 4-week intervals.
Doses were modified if hematologic and hepatic toxicities or
sensory neuropathy were encountered. Prophylactic colony-
stimulating factors were not allowed. They were permitted in
the setting of severe febrile neutropenia or life-threatening
infection. Erythropoietin was allowed to maintain hemoglo-
bin levels of 11 g/dl or greater. Carboplatin (area under the
curve, 2) and paclitaxel (50 mg/m2) were administered
weekly during radiotherapy, after review of weekly blood
tests. Chemotherapy was discontinued if hematologic or he-
patic toxicity was excessive.
Radiation therapy was to begin in week 9 (day 57 14
days), and two target volumes (TVs) were used. The first
(TV1) included the mediastinum from the thoracic inlet to the
subcarinal space, ipsilateral hilum, and bilateral mediastinal
(N2) nodes. The supraclavicular fossae were not to be treated
routinely, but treatment was permissible when high paratra-
cheal nodes were known to be involved by tumor or when the
location of the primary tumor in the upper lobe made their
avoidance difficult. Contralateral hilar coverage was not nec-
essary unless gross adenopathy (1 cm) was present. This
volume included the primary tumor and all lymph nodes of
size 1.0 cm or greater on CT scan, with a margin of 1.5 to 2.0
cm. Volumes were derived from a treatment planning CT
scan obtained before initiation of chemotherapy, unless there
was progression of intrathoracic disease during induction
chemotherapy, in which case the larger TV was to be used.
Patients were simulated pre and postchemotherapy, and the
union of these planning CTs was used to determine the
planned tumor volume. TV2 included only the known tumor
volume as defined on CT (primary tumor and lymph nodes
1.0 cm) and any nodal sites proven to be involved by
invasive staging, with a margin of 1.0 to 1.5 cm. Fifty Gy
were to be delivered to TV1, with a cone down to TV2 for an
additional 24 Gy in 1.8 to 2 Gy fractions. Nominal tumor
dose was stipulated to be 74 Gy (5%). All fields were to be
treated every week-day for a total treatment duration of 8
weeks. Tissue heterogeneity corrections and posterior cord
blocks were not permitted. The protocol-recommended max-
imal lung volume to receive 2000 cGy of radiation was 37%;
however, a precise definition of “lung” was not provided. The
maximum permissible doses were 50 Gy to the spinal cord,
40 Gy to the heart (50% of the heart was permitted to receive
50 Gy), and 64 Gy to the esophagus.
Response, Survival, and Toxicity Assessment
Patients were assessed for response after induction
chemotherapy (during week 8 from treatment initiation) and
again after chemoradiation (during weeks 25–26 and 8–9
weeks after completion of chemoradiation) using both CT
and PET scans. Radiographic response was expressed as a
continuous variable by calculating the percentage of change
in the sum of all greatest tumor diameters comparing the
posttreatment with pretreatment scans ([1  sum postlesions/
sum prelesions]  100; i.e., a reduction in tumor diameters
after therapy has a positive value and an increase a negative
value) and also by RECIST as best confirmed response.13 OS
was defined as the interval between the date of diagnosis and
the date of death. Progression-free survival (PFS) was defined
as the interval between the date of first therapy and the date
of progression or death. Local PFS was defined as the interval
between the date of first therapy and the date of local (in the
field of radiation) progression or death. Patients without an
event were censored as of the date of last follow-up. Kaplan-
Meier estimates were generated to describe the OS, PFS, and
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local PFS. Toxicity was monitored and documented accord-
ing to the common terminology criteria for adverse events
(CTCAE, version 3.0).
Dedicated Tumor Biopsies for Molecular
Studies
The trial mandated a tumor biopsy of an index lesion
before treatment initiation. A second and third tumor biopsy
were requested if they could be performed safely before
chemoradiation (week 8) and 8 weeks after completion of
chemoradiation (weeks 25–26). For specimens collected by
transthoracic biopsy, a 19-gauge guiding needle was placed
under CT guidance. A 20-gauge core biopsy gun device with
a 1 to 2 cm throw was then passed coaxially through the
guiding needle for up to six passes. Collected samples were
immediately frozen in liquid nitrogen and processed as de-
scribed previously.12
RESULTS
Patient Characteristics
Between November 2003 and March 2006, 43 patients
with stage IIIA/IIIB NSCLC were accrued. Four patients
withdrew consent before treatment initiation. Two did so
after the protocol-mandated tumor biopsy (both desired treat-
ment closer to home), one did not want to delay treatment
initiation, and one was uncomfortable with radiotherapy. The
clinical characteristics of the 39 patients who initiated the
protocol-specified therapy are listed in Table 1.
Chemotherapy Dosing and Toxicity
Induction chemotherapy was completed on schedule
without dose reduction in 28 (72%, 28/39) patients (Table 2).
Seven patients had 1-week dose delays, and four had dose
reductions or omissions for severe cytopenia or other toxicity.
One patient developed severe heart failure and did not receive
further therapy. Thirty-eight patients began concurrent che-
motherapy and radiation. Nineteen received all weekly doses,
and 19 had dose modifications (Table 2).
Radiation Dosing and Toxicity
Twenty-three patients (61%, 23/38) received the pre-
scribed 7400 cGy. The mean dose was 7024 cGy delivered
over 7.5 weeks (Table 3). The main reason (N  10) for dose
reduction was the protocol-recommended V20 dosage. The
median V20 was 34% (7%), and it ranged from 20 to 44%.
Dose-volume histograms were used for V20 calculations, and
lung was defined as total lung minus gross tumor volume.
There were two exceptions: in one patient, lung was defined
as total lung minus planned tumor volume, and in the other,
lung was defined as total lung including the tumor volume
(the V20 in this patient was 44%).
Toxicities requiring treatment discontinuation were en-
countered in two patients. One patient (70-year-old woman)
received only 3400 cGy because of severe esophagitis; she
died 2 months later from bowel ischemia. The patient had
prior arterial stenting for atherosclerotic disease. The second
patient (61-year-old man) succumbed to a bowel perforation
requiring right hemicolectomy after 3600 cGy. This event
was judged to be unrelated to the patient’s malignancy or
therapy received. Treatment was interrupted for 1 week in
one patient (65-year-old man) because of dehydration, and
the total dose given was 7200 cGy.
Chemoradiation-specific toxicities (grade 3) encoun-
tered after treatment discontinuation included five patients
with pneumonitis, which resolved with steroid therapy in four
and led to oxygen dependence in one. Two additional patients
developed an ipsilateral hydropneumothorax 14 months after
completion of therapy without evidence of disease recur-
rence, and both died of respiratory failure 6 to 8 weeks after
the event. One patient developed an esophageal stricture
requiring dilatation 3 months after completion of therapy.
Survival and Recurrence Patterns
As of the index date for survival analysis, December
2009, six patients were alive without evidence for disease
progression, two patients were alive with disease progression,
TABLE 1. Characteristics of Patients Who Initiated Therapy
Age (yr)
Minimum 47
Maximum 87
Mean 64.2
Median 62.4
Race/ethnicity
White (1 Hispanic) 37
Black 1
Asian 1
Sex
Male 20
Female 19
Performance status
0 16
1 23
Clinical stage
IIB 1a
IIIA 20
IIIB 18
Histopathologyb
Adenocarcinoma 12
Squamous cell 12
Large cell 3
NSCLC (NOS) 12
Smoking status
Never 3
Current 14
Former 22
Smoking pack-years
Minimum 0
Maximum 102
Mean 42.7
Median 38.0
a This patient (T3N0M0 NSCLC) was enrolled with an institutional review
board-approved exception.
b In four patients, the diagnosis was established using the protocol-required biopsy
(2  NSCLC; 1  squamous cell carcinoma; and 1  large cell carcinoma).
NSCLC, non-small cell lung cancer; NOS, not otherwise specified.
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and 31 patients had died. The cause of death was disease
progression in 19 patients. Nine patients died of causes
unrelated to lung cancer or its treatment, and three patients
died of pulmonary causes or cachexia without clear evidence
for tumor progression or treatment-related toxicity. The me-
dian OS was 22.7 months (95% confidence interval [CI]:
19.7–25.8 months), the median PFS was 14.3 months (95%
CI: 9.8–18.8 months), and the median local PFS was 19.4
months (95% CI: 15.0–23.7 months; Figure 1). The 2-year
and 5-year OS rates were 49% and 19%, and the PFS rates
were 23% and 14%, respectively. Of the 23 patients with
disease progression, the sites of first recurrence were outside
of the field of radiation in 18 patients; and they were in-field
recurrences in seven patients (two had simultaneous in- and
out-of-field recurrences; Figure 2). The sites of first out-of-
field recurrence were brain in five, multiple lung nodules in
four, liver in two, and diverse other or simultaneous multiple
sites in seven patients. One additional patient had an in-field
recurrence subsequent to a cerebral recurrence, and one
patient succumbed to a second lung cancer after a cerebellar
recurrence of the first lung cancer.
Experience with Dedicated Tumor Specimen
Collection
Dedicated tumor sampling before treatment initiation
was a study entry criterion. The trial also requested a second
and third tumor biopsy if it could be performed safely after
induction chemotherapy and 2 months after completion of
chemoradiation. Thus, the first tumor sampling was com-
pleted in all 39 patients. In addition, two of the four eligible
patients who withdrew consent before treatment initiation had
tumor sampling. The procedures used included endoscopy in
15, mediastinoscopy in five (done as part of a standard-of-
care lymph nodal evaluation), and transthoracic core needle
biopsies (TTNBx) in 21 patients. There were a total of three
complications, all a result of TTNBx; two patients had small
pneumothoraces that did not require intervention; one patient
required chest tube placement, and he recovered completely
(the TTNBx in this patient also served to establish the
diagnosis).
The second tumor sampling was completed by endos-
copy in 11 and by TTNBx in 16 patients. One patient had a
small pneumothorax after TTNBx that did not require inter-
vention. The reasons for not collecting tumor in the remain-
ing 12 patients were a reduction in tumor size that precluded
safe sampling in nine patients and the use of anticoagulation
therapy, severe heart failure, and refusal in one patient,
respectively.
At the time of the third tumor sampling, 18 of 38
patients who had started chemoradiation could not be biop-
sied because of a substantial size reduction, two were de-
ceased, one refused, and three had biopsies withheld due to
concurrent medical issues. Samples were obtained by bron-
choscopy in three, by TTNBx in nine, and by ultrasound-
guided needle biopsy of sites of progression in two patients
(liver and supraclavicular lymph node). Two patients re-
quired chest tube placement after TTNBx, and both had a
complete recovery.
Three serial biopsies for tumor sampling were done in
13 patients and two in 15 patients (no. 1 and no. 2 in 14, no.
1 and no. 3 in one patient). Thirteen patients had only the first
biopsy (including the two patients who withdrew consent).
Thus, a total of 82 procedures were done resulting in three
complications that required an intervention, i.e., chest tube
placement for treatment of a pneumothorax as a result of a
CT-guided TTNBx.
DISCUSSION
Although bimodality concurrent chemoradiation has
been established as superior to a sequential approach, the
addition of chemotherapy before or after concurrent treatment
TABLE 2. Delivery and Toxicity of Induction and
Concurrent Chemotherapy
Induction Chemotherapy
Dose Reduction (%) Cycle Delay (%)
Cycle 1
D 8
Cycle 2
D 1
Cycle 2
D 8
Cycle 1
D 8
Cycle 2
D 1
Cycle 2
D 8
0 (0%) 3 (7.7%) 0 (0%) 1 (2.6%) 4 (10.2%) 3 (7.7%)
Reasons for Dose Reduction Reasons for Cycle Delay
Thrombocytopenia (n  1) Neutropenia (n  5)
Neutropenic fever (n  1) Thrombocytopenia (n  1)
Severe Reynaud’s (n  1)a Viral syndrome (n  1)
Elevated liver function tests (n  1)
Concurrent chemotherapy
Discontinuation (n  7)b Cycles Skipped (n  12)c
Allergic reaction (n  3) Neutropenia (n  4)
Ongoing thrombocytopenia
(n  1)
Thrombocytopenia (n  5)
Severe esophagitis (n  1)d Shortness of breath (n  2)
Cardiac failure (n  1)e Fever (n  2)
Neutropenia (n  1) Dehydration (n  1)
Colon perforation (n  1)e Gastroenteritis (n  1)
a Second induction cycle not delivered.
b One patient had more than one reason to discontinue chemotherapy.
c Several patients had more than one reason for not receiving chemotherapy.
d Chemotherapy discontinued.
e Patient taken off study.
TABLE 3. Delivery and Toxicity of Radiotherapy
Minimum Maximum Mean Standard Deviation
Dose (cGy) 3400 7400 7024 695
Elapsed days 23 67 53 8
Discontinuation (n  2) Dose Reduction (n  13)
Esophagitis after 3400 cGy (n  1) Unacceptable V20a (n  10)
Bowel perforation (n  1, unrelated) Dosimetric concerns (n  1)
Unknown (n  1)
Patient refusal (n  1)
Volume of lung receiving
20 Gy 37%a
a Lung volume receiving more than 2000 cGy.
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remains controversial. Based on a multiinstitutional phase II
trial conducted by the Southwest Oncology Group, there was
considerable enthusiasm for continued chemotherapy after
completion of chemoradiation.10 In addition, a multiinstitu-
tional phase II trial randomized patients to induction carbo-
platin/paclitaxel (CbP) followed by 63 Gy of radiotherapy
alone or radiation and concurrent CbP. In a third arm, patients
received concurrent CbP and radiation followed by consoli-
dation CbP. Survival was longest (16.3 months median OS)
in the latter arm; however, these patients also had the greatest
toxicity.14 A recent randomized phase III trial conducted by
the Hoosier Oncology Group and US Oncology did not show
a survival benefit if consolidation chemotherapy was given
after chemoradiation.15
A single-institution retrospective analysis compared
265 successive patients who were treated with induction
chemotherapy followed by chemoradiation or chemoradiation
alone.6 Patients who received induction chemotherapy had
better OS (median, 22.8 versus 16.8 months; 5-year rate, 25%
versus 12%; p  0.001) and distant metastasis-free survival
(5-year rate, 42% versus 23%; p  0.021). Locoregional
control was not significantly different between the two
groups.
In 2007, Vokes et al.16 published results of a ran-
domized phase III trial of concurrent 66 Gy radiation and
CbP with or without two cycles of induction CbP. The
median OS was 14 months with and 12 months without
induction therapy, which was not statistically different.
The authors concluded that the addition of induction che-
motherapy to concurrent chemoradiation added toxicity
and provided no statistically significant survival benefit
over concurrent chemoradiation alone. Nevertheless, the
median survival in both groups was low, and the authors
recommended that concomitant weekly CbP should be
reexamined.
A European randomized phase III trial used an alternate
chemotherapy regimen.17 It consisted of cisplatin (60 mg/m2),
gemcitabine (1000 mg/m2, days 1 and 8), and vinorelbine (25
mg/m2, days 1 and 8) given as induction or consolidation
therapy for two cycles; and concomitant chemotherapy was
cisplatin (60 mg/m2) and vinorelbine (15 mg/m2) given on days
1 and 22 and gemcitabine (200 mg/m2) given on days 8 and 29
together with 66 Gy of radiation. The trial accrued poorly and
was terminated early with 49 patients enrolled. Median OS was
23.9 months in the induction arm compared with 17.0 months in
the consolidation arm.
The escalation of radiation doses is being pursued as an
alternate approach to improving patients’ outcome. In a phase
I/II radiation, dose-escalation trial of induction CbP followed
by concurrent radiation and CbP, 74 Gy of radiotherapy was
established as the maximal tolerated dose.7–9 The investiga-
tors enrolled a total of 62 patients and reported a median OS
of 24 months. In a subsequent trial with a modified induction
regimen but the identical concurrent chemotherapy, these
investigators escaladed the radiation dose to 90 Gy, which
FIGURE 1. The median overall sur-
vival (OS) for all 39 patients was
22.7 months (black curve), the me-
dian progression-free survival (PFS)
was 14.3 months (red curve), and
the median local PFS was 19.4
months (blue curve). At 2 years, the
OS rate was 49%, the PFS rate was
23%, and local PFS rate was 33%.
Tick marks indicate censoring
events.
FIGURE 2. Venn diagram of patterns of first recurrence.
The predominant sites of distant recurrences were brain,
lung, and liver. Ten patients are deceased, and six are alive
without evidence for recurrence.
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resulted in two instances of bronchial stenosis and two fatal
hemoptysis.18
Using the established safe dose of 74 Gy, Socinski et
al.19 conducted a randomized phase II trial of induction
chemotherapy followed by concurrent chemoradiation with
two different chemotherapy regimens. One group received
CbP in 3-weekly cycles during the induction phase with
weekly dosing during radiation. The other group received
carboplatin/gemcitabine induction followed by biweekly sin-
gle-agent gemcitabine (35 mg/m2) during radiation. Because
of an unacceptable rate of grade 4/5 pulmonary toxicity (4/26
patients), the gemcitabine-containing arm was closed early.
Analysis of the 3D-conformal treatment plans showed that
the V20 (volume of lung receiving 20 Gy) exceeded 40% in
two of three plans (the V20 was unavailable in the fourth
patient). The median OS was 24.3 months for patients receiv-
ing the paclitaxel-containing regimen.
The results of our study with a median OS of 22.7
months in 39 patients compare favorably with these previ-
ously published results. As our trial had a nonrandomized
single-institution design, a potential bias toward beneficial
outcome may exist; although our eligibility criteria are con-
sistent with those used in most trials for patients with locally
advanced NSCLC. The chemotherapy selected for our trial
combined a gemcitabine-based induction with a taxane-based
concomitant regimen and high-dose conformal radiation to 74
Gy. Our data suggest that this approach is safe, feasible, and
comparable in toxicity to the above reference non-gemcitab-
ine regimens. Nevertheless, disease progression within and
outside the radiation fields remains a problem. Radiotherapy
has advanced substantially since our trial was designed,
including the use of 4D treatment planning, treating only
PET-positive disease, daily image guidance with planned
tumor volume reduction, and intensity-modulated radiation
therapy. These technologies offer the potential to simulta-
neously increase the dose to tumor while reducing normal
tissue toxicity. In addition, better selection of systemic ther-
apy based on molecular characteristics of the tumor may lead
to a reduction of distant recurrences. We demonstrated in our
trial that dedicated tumor collection before and during ther-
apy is safe, feasible, and acceptable for patients with NSCLC.
Future trials that seek to incorporate molecular investigations
can use our rates of serial tumor collections as a guide for
selecting adequate patient volumes for correlative studies.
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